Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Alnylam Pharmaceuticals, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $39.0B | |
|---|---|---|
| Revenue (ttm) | 4.8B | |
| Net income (ttm) | 774.7M | |
| EPS (ttm) | $5.62 | |
| Shares out | 133.8M | |
| P/E (trailing) | 41.4x | |
| P/E (forward) | 21.1x | |
| Volume | 1,406,686 | |
| Beta | 0.27 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $1.04B | $1.83B | $2.25B | $3.71B | +53.0% |
| Gross profit | $868.6M | $1.52B | $1.92B | $3.03B | +51.7% |
| Operating income | $-971.0M | $-312.3M | $-235.5M | $575.8M | — |
| Net income | $-1.13B | $-440.2M | $-278.2M | $313.7M | — |
| EPS (diluted) | $-9.30 | $-3.52 | $-2.18 | $2.33 | — |
| EBITDA | $-926.6M | $-258.2M | $-178.8M | $631.4M | — |
| R&D | $883.0M | $1.00B | $1.13B | $1.32B | +14.3% |
| SG&A | $770.7M | $795.6M | $975.5M | $1.21B | +16.3% |
Recent company headlines from major financial publishers.
RNAi becomes the standard of care for massive prevalent indications like hypertension and obesity. Operating margins blow past 35% due to hyper-scale manufacturing efficiencies.
ALNY successfully bridges its rare disease dominance into prevalent markets, achieving extreme operating leverage and commanding a premium platform multiple.
| Ke ↓ / g → | 2.5% | 3.0% | 3.5% | 4.0% | 4.5% |
|---|---|---|---|---|---|
| 5.0% | $936 | $1,165 | $1,165 | $1,165 | $1,165 |
| 6.0% | $666 | $778 | $936 | $1,165 | $1,165 |
| 7.0% | $516 | $582 | $666 | $778 | $936 |
| 8.0% | $422 | $464 | $516 | $582 | $666 |
| 9.0% | $366 | $386 | $422 | $464 | $516 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
